IIM
NBIX icon

Illumine Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Illumine Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,632
Closed -$1.43M – 40
2026
Q1 		$1.27M Sell
9,632
-24
-0.2% -$3.18K 0.98% 41
2025
Q4 		$1.37M Sell
9,656
-80
-0.8% -$11.6K 1% 40
2025
Q3 		$1.37M Sell
9,736
-143
-1% -$19.4K 0.97% 39
2025
Q2 		$1.24M Buy
9,879
+238
+2% +$27.3K 0.99% 36
2025
Q1 		$1.07M Buy
9,641
+139
+1% +$17.6K 0.87% 40
2024
Q4 		$1.3M Buy
+9,502
New +$1.18M 1.07% 37

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Illumine Investment Management's NBIX Position: Q2 2026 in Review

Illumine Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 9,632 shares — an estimated $1.43M sold.

Illumine Investment Management first reported a position in NBIX in Q4 2024 and held it in 6 quarters. The position peaked at $1.37M in Q4 2025. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Illumine Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Illumine Investment Management sold 9,632 Neurocrine Biosciences shares in Q2 2026, an estimated $1.43M.
  • Illumine Investment Management first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 6 quarters.
  • Illumine Investment Management's Neurocrine Biosciences position peaked at $1.37M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Illumine Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.